As an Executive Director of New Business Development, I lead strategic initiatives focused on driving business growth and expansion. With an entrepreneurial mindset and sharp strategic vision, I am responsible for identifying new market opportunities, building strategic partnerships, and leading market entry efforts.

In my role as the Virology Business Unit Director, I had direct reports in both marketing and sales.I oversee four therapeutic areas: Hepatitis C, Hepatitis B, COVID-19, and HIV. Approximately 90% ofour portfolio was dedicated to the public sector, and this allowed me to accumulate significantexperience in federal acquisitions.In the private sector, I was responsible for conducting market analyses to identify trends,opportunities, and threats, and discussing strategies as necessary for oncology, hematology,and rheumatology in my role as Marketing Director overseeing portfolio analysis.During the pandemic, I had the opportunity to launch the antiviral drug, Remdesivir, where I facedand successfully navigated the challenges of that moment. Until October 2022, I also held theresponsibility for the digital marketing department within our affiliate. I had a Digital Managerreporting to me, and I was in charge of driving digital transformation efforts within the Brazil affiliate.

I am responsible for the Neonatology Business Unit, where the main focus is the implementation of federal reimbursement published by the Ministry of Health in 2013. Direct participation in building the business unit and in Resource Allocation analysis to define sectors, market potential and awards.Leading the sales force directly with effectiveness programs and implementation of marketing initiatives. Building the annual and 5 year marketing plan, including the patient's journey, P&L management, and goal setting of Marketing and Sales Force.Leading Brand Team meetings, supply chain and forecast development.Member of the Synagis Brand Council, participating of all international meetings analyzing trends in brand strategy and global portfolio management. Excellent relationship with the leadership in Latin America. Active participation in negotiating centralized purchasing by the Ministry of Health.Managing private market initiatives, optimizing strategies with health plans and defining in-hospital dose pricing.Excellent relationship with brand opinion leaders and access managers representing the brandAnalyzing the constant search for talents, proposing action plans together with direct reports.Support in the management of patients program that meet the Synagis brand

I was in charge of promoting the product Temodal – 2nd product in sales at MSD, and the Supportive Care line with the products Onicit and Emend.Launching the product PegIntron in the melanoma indication.Development of pre-marketing and definition of strategy for Jenzyl and Zolinza productsManagement of an outsourced team of nurses who promote Supportive Care line.Oncology team management consisting of: 1 product manager, 1 marketing analyst, 1 job rotation (sales representative) and 1 intern.

I was responsible for repositioning the product Remicade in 03 rheumatologic indications: Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis.Mapping the public market on indications of Ankylosing Spondylitis and Psoriatic Arthritis when not reimbursed by the federal government.Pre marketing and pre-launch of the product Simponi.Management and maintenance of the Patient Program MSD Fique Bem (Be Well).Implementing the tools RADAR and PRL tool for new products in Brazil.Co-positioning study for the products Remicade and Simponi in Brazil.Active role in the "Emerging Markets" study for Remicade together with McKinsey & CompanyPR activities for Remicade and Simponi.Active role in building negotiation scenarios with the health ministry with the centralized sale of Remicade.Direct involvement in the GO-More clinical study for Simponi.Brazilian representative in the global task force for the launch of Simponi.Ensuring the accuracy of sales and promotion.Close relationship with several stakeholders (opinion leaders, patient organizations, medical societies, nurses, infusion clinics, pharmacists)Jointly with the training area responsible for all programs aimed at the sales force for both products.Developing proposals for promotion and partnerships for private health plans.Direct participation throughout the start-up of the arrival of Remicade in MSD before at Mantecorp.Structuring and development of the RAISE project in Brazil - anchor activity for the pre marketing of Simponi.Transition of Remicade and Simoni to Janssen-Cilag

Synagis Senior Product Manager 2009 – 2007I was in charge of product standardization in the states of São Paulo and Rio de JaneiroBuilding the dossier for submission and incorporation into the Federal MinistryProduct entry into the Brazilian guidelinesLaunching of the patient program Synergia (receiving the Lupa de Ouro award in 3rd place)Development and coordination of access work to the private marketDevelopment and coordination of the marketing campaign for physicians and patients out of product seasonality

Depakote Senior Product Manager 2007 – 2004Repositioning the product in the indication for Bipolar Disorder (receiving the Lupa de Ouro award in 1st place)Re-launching in the indication for MigrainesLaunching the presentation "Extended Release"Launching the campaign "A Arte rompendo barreiras” (Art breaking obstacles) for epileptic patients in conjunction with the Epileptic Patient Association Depakote took the lead among the mood stabilizers used to treat Bipolar Disorder becoming the second product in sales in the primary care division.